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Introduction: Pegylated irinotecan NKTR-102 is a topoisomerase I inhibitor-polymer conjugate. This new formulation
of irinotecan has been evaluated in a phase II clinical trial and is showing remarkable activity. To the best of our
knowledge, this is the first case report of an impressive iterative response to pegylated irinotecan NKTR-102 in
metastatic breast cancer.
Case presentation: We report the case of a 49-year-old Caucasian woman diagnosed with metastatic luminal A breast
cancer with initial bone followed by liver and bone marrow metastases, treated with three lines of hormonal therapy,
targeted therapy and six lines of chemotherapy. She showed no major response to conventional treatment, whereas,
the tumor shrinkage under pegylated irinotecan NKTR-102 was impressive, durable and iterative.
Conclusions: Reintroduction of an active drug is a valid approach as illustrated by our case. The results of the current
phase III trials of pegylated irinotecan NKTR-102 are eagerly awaited.
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Metastatic breast cancer is an incurable disease. Sys-
temic therapy aims to prolong disease control while pre-
serving good quality of life. During past years, many
drugs have been developed and have proven efficacy,
leading to some prolongation of overall survival. The ac-
tive search for new anticancer drugs continues while
new formulations of the existing ones are also being pur-
sued. Irinotecan, a topoisomerase I inhibitor and a major
cytotoxic drug for some tumor types, has limited activity
in breast cancer. Thus, it has been reformulated by pegy-
lation, in order to reach a durable high concentration in
tumor tissue, with the hope that its antitumor spectrum
activity will be broadened. This new formulation,
NKTR-102, has shown promising activity in phase II
studies and it is currently being evaluated in phase III
clinical trials [1]. We report the case of a patient, en-
rolled in a clinical trial with pegylated irinotecan, who* Correspondence: mounia.amzerin@gmail.com
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the drug’s reintroduction.
Case presentation
A 49-year-old premenopausal Caucasian woman was
diagnosed in June 2006 with stage IV luminal A breast
cancer and bone metastases. She had a medical history
of smoking during fifteen years, grade A esophagitis
(Savary and Miller classification) and an iodine allergy.
She had no family history of cancer. Since luminal A
breast cancer is hormone-sensitive and she was asymp-
tomatic, she received a first-line hormonal therapy con-
sisting of tamoxifen (20mg, once daily) combined with a
luteinizing hormone-releasing hormone agonist every
three months, resulting in a partial response after six
months. She underwent a lumpectomy, sentinel node
biopsy and concomitant surgical castration. Tamoxifen
was continued after her surgery. The disease progressed
three months later with the emergence of liver metasta-
ses. She received anastrozole (1mg, once daily) + gefitinib
(250mg, per day) in a clinical trial, with disease pro-
gression after three months. Her treatment was then
switched to chemotherapy associating cyclophosphamidel. This is an Open Access article distributed under the terms of the Creative
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weeks), which induced a partial response after three and a
half months (six cycles). Exemestane (25mg, daily) was
given as a maintenance treatment until the disease pro-
gressed 15 months later; her CA 15-3 level increased, new
liver metastases appeared and an osteo-medullary infiltra-
tion was diagnosed.
She was treated with docetaxel (100mg/m2, every
three weeks) and showed a good response after four and
half months (seven cycles). After a short treatment break
of two months, the disease progressed once more; the
CA 15-3 level was 102UI/mL. She was enrolled in a clin-
ical trial and received pegylated irinotecan NKTR-102 at
145mg/m2 every two weeks. After one and a half
months, the response assessment showed a partial radio-
logical response of the liver metastases according to
RECIST (Figure 1), and the CA 15-3 marker level had
decreased to the normal range. The response was main-
tained for five and a half months (12 cycles; Figure 2A)
but the treatment had to be stopped due to uninter-
rupted grade 3 diarrhea (NCI-CTC scale, version 4.0).
Four months later, further liver metastases shrinkage
was noted even in the absence of treatment (Figure 2B).
She enjoyed a period of disease stability with no treat-
ment for 18 months.
After this period, liver metastases were found to have
progressed and pegylated irinotecan was reintroduced.
This, once again, induced a 50% partial radiological re-
sponse and a decrease of the CA 15-3 level from 896 to
173UI/mL after three cycles. Her liver disease continued to
respond for an additional eight months, until it progressed
in September 2012. The main toxicities caused by NKTR-
102 were alopecia, diarrhea, asthenia and anorexia, all
grade I (NCI-CTC scale, version 4.0). There was no cumu-
lative toxicity. She then received capecitabine (1250mg/m2,
twice daily from day one to 14, every three weeks), but liver
metastases progression was documented after only four
months. She subsequently received eribulin (1.23mg/m2,
every three weeks) as the fifth line of chemotherapy. HerFigure 1 Tumor response after the first three cycles of NKTR-102. A: B
metastasis. B: Abdominal computed tomography scan showing a partial reliver disease progressed once again in the fifth month of
treatment. She underwent a biopsy of a liver metastasis
which revealed a non-hormone-sensitive Her2+ tumor
clone. She received a sixth line of chemotherapy consisting
of weekly paclitaxel combined with trastuzumab and zole-
dronate. Her liver disease was in complete response while
her bone metastases remained stable. Eight years after the
initial diagnosis, she is still surviving and is currently under
a maintenance therapy consisting of letrozole, trastuzumab
and denosumab for her bone lesions.
Discussion
Irinotecan is a topoisomerase I inhibitor approved for
the treatment of metastatic breast cancer in Japan [2].
An objective response rate (ORR) of 23% was obtained
in an American phase II study which was comparable to
Japanese literature data [3,4]. In European metastatic
breast cancer patients, irinotecan has a reputation of
having limited activity in advanced breast cancer [2,5].
That said, clinical trials with irinotecan in metastatic
breast cancer are limited [6].
Pegylated irinotecan NKTR-102 is a long acting topo-
isomerase I inhibitor [7]. It was obtained by conjugating
irinotecan to a four-arm polyethylene glycol [8]. This in-
teresting new formulation achieves an elimination half-life
of the active metabolite SN-38 of 50 days, compared to
two days with irinotecan, while the peak concentrations
are five to 10 times lower [7]. Thus, there is an uninter-
rupted exposure to SN-38 and less toxicity [7]. This had
been illustrated by preclinical data demonstrating the su-
periority of pegylated irinotecan NKTR-102 to irinotecan
in lung, breast and colorectal mouse xenografts models
[9]. Phase I studies showed an encouraging activity in vari-
ous solid tumors and recommended a dose of 145mg/m2
every 14 or 21 days for phase II clinical trials [7]. Subse-
quent phase II studies revealed remarkable objective re-
sponse rates in taxane-refractory metastatic breast cancer
(29%) and platinum-resistant or refractory ovarian cancer
(20%), respectively [1,10].aseline abdominal computed tomography scan showing liver
sponse after three cycles of pegylated irinotecan NKTR-102.
Figure 2 Tumor response after NKTR-102 discontinuation. A: Partial response at the 12th cycle of pegylated irinotecan NKTR-102. B: Abdominal
computed tomography scan four months after the last course of pegylated irinotecan NKTR-102, showing additional response.
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the goal of systemic therapies is to achieve prolonged
disease stabilization while maintaining quality of life.
Our patient experienced an objective response to the
successive lines of chemotherapy and endocrine therapy
she received. However, the disease was progressing each
time after a short period of chemotherapy. The literature
provides little data regarding prolonged tumor responses
under chemotherapy. Anectotal durable remissions have
been observed with capecitabine, gemcitabine and vino-
relbine (Table 1) [11-13]. Long remissions have mainly
been reported with biological treatments [14,15]. For
our patient, the introduction of pegylated irinotecan
NKTR-102 gave, for the first time, a durable response
with manageable toxicity. Interestingly, disease regres-
sion continued even after the treatment was stopped.
This illustrates the particularity of NKTR-102’s pharma-
cokinetic profile, namely, conferring longer half time
and more prolonged exposure to the active drug.
The durable remission for 18 months without any main-
tenance treatment is another interesting feature in our
case. This could be partially explained by the ‘favorable’
histology of the disease, however, the other treatments
provided only short periods of remission. Therefore, we
suggest that pegylated irinotecan NKTR-102 played a role
in this prolonged control of the disease, by some mechan-
ism which remains to be elucidated.Table 1 Prolonged progression-free survival (PFS)
anecdotally reported in metastatic breast cancer
refractory to anthracyclines and taxanes
Drug Prolonged PFS (months) observed
individually in the literature
Reference
Eribulin NR
Vinorelbine 12 for responding patients Zelek et al. [11]
Ixabepilone NR
Capecitabine 12 Rogers et al. [12]
Gemcitabine 23 Schmid et al. [13]
NR: Not reported.After the sustainable impressive response to pegylated
irinotecan NKTR-102, the decision to reintroduce it after
disease progression seemed logical in view of the fact that
our patient had enjoyed a good response in the one year
before her liver metastases started to progress again. After
an initial response and a prolonged progression-free inter-
val, the reintroduction of an active drug in front of tumor
progression is a common practice since one assumes no
resistance to the drug has developed. The case of our pa-
tient confirms the validity of this approach.
Our patient belongs respectively to the ranges of 0 to
37% [16] and 14.5 to 40% [16] of patients who expe-
rience the acquisition of a Her2+ profile and the dis-
cordance in estrogen ER and progesterone PR receptors
expression. A novel biopsy was very useful in this case
since a completely different clone of tumor cells was
identified and she could be offered a more personalized
treatment option.
Conclusions
The case of our patient illustrates the huge progress made
in the management of breast cancer. Thanks to clinical re-
search, more treatments and options are currently avail-
able. This allows patients to enjoy prolonged remissions
and improved survival. The identification of a new tumor
clone made in our case supports the notion that a biopsy
of metastatic sites in cases of disease progression is not a
luxury but a necessity. In addition, as stated above, the
new design and formulation of a known drug can be an
elegant way of broadening its antitumor spectrum. Pegy-
lated irinotecan NKTR-102 is currently being evaluated in
a phase III pivotal trial for metastatic breast cancer after
anthracyclines, taxanes and capecitabine [17]. Results
from this trial are eagerly awaited.
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